CAMBRIDGE, Mass. (AP) — BIND Therapeutics said Wednesday that Pfizer Inc. has agreed to pay at least $160 million per drug as part of a collaboration to develop targeted medicines using nanotechnology which use particles measured in billionths of a meter.

BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease and inflammatory disorders. The privately held company’s technology comes from two laboratories that specialize in nanotechnology at Harvard Medical School and the Massachusetts Institute of Technology.

Recommended Stories

Pfizer to pay record $2.3 billion settlement

Trump highlights healthcare plan amid Democrats’ shutdown narrative

Connecticut, Pfizer announce use of Groton site